Progressive Supranuclear Palsy News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Early biomarker found for degenerative neurologic disease
(Society of Nuclear Medicine and Molecular Imaging) Researchers have discovered a novel radioligand that can effectively differentiate progressive supranuclear palsy (PSP) from similar brain disorders, allowing for earlier and more reliable diagnosis of the disease. Presented at the Society of Nuclear Medicine and Molecular Imaging's 2019 Annual Meeting, these findings bring physicians a step closer to being able to definitively diagnose PSP with imaging rather than waiting for confirmation upon autopsy. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 22, 2019 Category: Biology Source Type: news

#MayoClinicRadio podcast: 6/8/19
Listen: Mayo Clinic Radio 6/8/19 On the Mayo Clinic Radio podcast, Dr. Amy Degnim, a Mayo Clinic breast cancer surgeon, discusses breast cancer screening guidelines from The American Society of Breast Surgeons. Dr. Degnim also discusses advances in breast cancer surgery. Also on the podcast, Dr. Bradley Boeve, a Mayo Clinic neurologist, explains progressive supranuclear palsy, a rare brain [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 9, 2019 Category: Databases & Libraries Source Type: news

Mayo Clinic Minute: What you need to know about progressive supranuclear palsy
Progressive supranuclear palsy is a relatively rare but devastating neurologic disease. Dr. Bradley Boeve, a Mayo Clinic neurologist, says without a cure or effective treatments, it's a difficult illness to control. Watch: The Mayo Clinic Minute https://youtu.be/BodIBhEMpD4 Journalists: Broadcast-quality video pkg (0:59) is in the downloads at the end of the post. Please "Courtesy: Mayo [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 20, 2019 Category: Databases & Libraries Source Type: news

Asceneuron Appoints Peter Van Vlasselaer as Chairman
Serial biotech entrepreneur joins leading small molecule tau modulation company LAUSANNE, Switzerland and CAMBRIDGE, Ma., January 17, 2019 -- (Healthcare Sales & Marketing Network) -- Asceneuron, an emerging leader in the development of orally bioavail... Biopharmaceuticals, Neurology, Personnel Asceneuron, Progressive Supranuclear Palsy, tau pathology (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 17, 2019 Category: Pharmaceuticals Source Type: news

Traumatic brain injury and firearm use and risk of progressive supranuclear palsy among veterans - Kelley KD, Checkoway H, Hall DA, Reich SG, Cunningham C, Litvan I.
Background: Progressive supranuclear palsy (PSP) is a tauopathy that has a multifactorial etiology. Numerous studies that have investigated lead exposure and traumatic brain injury (TBI) as risk factors for other tauopathies, such as Alzheimer's dis... (Source: SafetyLit)
Source: SafetyLit - July 11, 2018 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Blink Reflex Recovery Cycle May Distinguish PSP From CBD Blink Reflex Recovery Cycle May Distinguish PSP From CBD
For indeterminate diagnoses, the R2 blink reflex recovery cycle can help distinguish between progressive supranuclear palsy and corticobasal degeneration, a study shows.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 12, 2017 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Palliative care and its emerging role in Multiple System Atrophy and Progressive Supranuclear Palsy
This review aims to discuss the trajectory of disease in MSA and PSP, explore significant symptoms and summarize some evidence which exists for palliative care need and quality of life in these conditions. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 28, 2017 Category: Consumer Health News Source Type: news

Progressive Supranuclear Palsy
(Symptoms, Stages, Treatment, and Life Expectancy) (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 3, 2017 Category: Journals (General) Source Type: news

Bristol-Myers Squibb enters into separate agreements with Biogen and Roche to License anti-eTau and anti-myostatin compounds
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for Progressive Supranuclear Palsy (PSP), to Biogen (NASDAQ:BIIB), and BMS-986089, an anti-myostatin adnectin in development for Duchenne Muscular Dystrophy (DMD), to Roche. (Source: World Pharma News)
Source: World Pharma News - April 13, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Silverado Parkinson's Disease and Movement Disorders Program
Program focuses on needs of those with Parkinson ' s disease and other movement disorders, such as Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD) and Multiple System Atrophy (MSA) (Source: Disabled World)
Source: Disabled World - February 19, 2017 Category: Disability Tags: Parkinson ' s Disease Source Type: news

A protein called PERK may be a target for treating progressive supranuclear palsy
(DZNE - German Center for Neurodegenerative Diseases) The brain disease 'progressive supranuclear palsy' (PSP) is currently incurable and its symptoms can only be eased to a very limited degree. PSP impairs eye movements, locomotion, balance control, and speech. Scientists at the DZNE and the Technical University of Munich (TUM) have now discovered a molecular mechanism that may help in the search for effective treatments. A team of researchers led by G ü nter H ö glinger reports on this in the journal 'EMBO Molecular Medicine'. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 6, 2017 Category: Global & Universal Source Type: news

AbbVie begins Phase II trial of ABBV-8E12 to treat Alzheimer's and PSP
US-based biopharmaceutical firm AbbVie has begun Phase II clinical trial programmes of its ABBV-8E12 antibody to treat patients with early Alzheimer's disease and progressive supranuclear palsy (PSP). (Source: Drug Development Technology)
Source: Drug Development Technology - January 27, 2017 Category: Pharmaceuticals Source Type: news

Understanding falls in progressive supranuclear palsy - Bluett B, Litvan I, Cheng S, Juncos J, Riley DE, Standaert DG, Reich SG, Hall DA, Kluger B, Shprecher D, Marras C, Jankovic J.
INTRODUCTION: Progressive supranuclear palsy (PSP) is characterized by frequent falls which worsen with disease progression, causing substantial morbidity and mortality. Few studies have investigated which factors contribute to falls in PSP, and all have i... (Source: SafetyLit)
Source: SafetyLit - December 30, 2016 Category: Global & Universal Tags: Age: Elder Adults Source Type: news

Progressive Supranuclear Palsy
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - December 8, 2015 Category: Journals (General) Source Type: news